Diabetes and percutaneous coronary intervention in the setting of an acute coronary syndrome

Diab Vasc Dis Res. 2005 Oct;2(3):128-35. doi: 10.3132/dvdr.2005.020.

Abstract

Diabetes mellitus has reached epidemic proportions worldwide. Patients with diabetes are at increased risk for acute coronary syndromes, and these syndromes lead to frequent morbidity and cardiovascular mortality. Emerging adjunctive pharmacological strategies coupled with the drug-eluting stent platform have resulted in improved adverse event rates for this high-risk group. This review will concentrate on the historical data associated with acute coronary syndromes in diabetes mellitus, focusing on revascularisation, drug-eluting stents and antiplatelet therapies.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Angioplasty, Balloon, Coronary*
  • Coronary Artery Bypass
  • Coronary Disease / drug therapy
  • Coronary Disease / therapy*
  • Coronary Restenosis / etiology
  • Coronary Restenosis / prevention & control*
  • Diabetes Complications / drug therapy
  • Diabetes Complications / therapy*
  • Humans
  • Paclitaxel / therapeutic use
  • Platelet Aggregation Inhibitors / therapeutic use
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Purinergic P2 Receptor Antagonists
  • Randomized Controlled Trials as Topic
  • Sirolimus / therapeutic use
  • Stents* / statistics & numerical data
  • Syndrome

Substances

  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Purinergic P2 Receptor Antagonists
  • Paclitaxel
  • Sirolimus